Scarica l'app Stockscreener
2.30
8.00%
-0.20
Precedente Chiudi:
$2.50
Aprire:
$2.38
Volume 24 ore:
396.85K
Relative Volume:
0.99
Capitalizzazione di mercato:
$115.65M
Reddito:
$17.63M
Utile/perdita netta:
$-57.71M
Rapporto P/E:
-1.5541
EPS:
-1.48
Flusso di cassa netto:
$-60.45M
1 W Prestazione:
-24.34%
1M Prestazione:
-28.35%
6M Prestazione:
-47.00%
1 anno Prestazione:
-55.85%
Intervallo 1D:
$2.29
$2.4392
Intervallo di 1 settimana:
$2.20
$3.06
Portata 52W:
$2.20
$5.65
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Nome
Scpharmaceuticals Inc
Settore
Industria
Telefono
617-517-0730
Indirizzo
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Confronta SCPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
2.30 | 115.65M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-07 | Iniziato | Craig Hallum | Buy |
| 2022-12-01 | Iniziato | Cowen | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-10-11 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Iniziato | Maxim Group | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-30 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mostra tutto
Scpharmaceuticals Inc Borsa (SCPH) Ultime notizie
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
scPharmaceuticals Readies Major Financial Update: Q4 and Full Year Results Coming March 19 - Stock Titan
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD - Pharmacy Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the ... - The Bakersfield Californian
FUROSCIX Scores Crucial FDA WinNew CKD Treatment Could Transform Patient Care - StockTitan
SCPH stock touches 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
SCPH stock touches 52-week low at $3.07 amid market challenges - Investing.com India
FY2029 Earnings Forecast for SCPH Issued By HC Wainwright - Defense World
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
scPharmaceuticals (SCPH) Projected to Post Quarterly Earnings on Wednesday - Defense World
A look into scPharmaceuticals Inc (SCPH)’s deeper side - SETE News
scPharmaceuticals (NASDAQ:SCPH) Receives “Buy” Rating from HC Wainwright - Defense World
Scpharmaceuticals Inc Azioni (SCPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):